iShares Global Healthcare

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

AstraZeneca and Daiichi Sankyo's Enhertu Approved by FDA for HER2+ Early Breast Cancer

AstraZeneca's Baxfendy Approved in US, Outpacing Mineralys Therapeutics

AstraZeneca and Roche Diagnostics APAC Partner to Develop Advanced Pathology Solutions for Breast and Lung Cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Barclays Remains a Buy on Bayer (0P6S)

BAYRY

SBIO

LABU

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

NBIX

SLNO

ARKG

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

nasdaq

Neurocrine Biosciences

Soleno Therapeutics

Ark Genomic Revolution ETF

VG Health

Goldman Sachs

Nasdaq

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

BAYN

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UNHG

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

Market Beat

Unitedhealth

iShares US Healthcare Providers

SPDR S&P Health

Leverage Shares 2X Long UNH Daily ETF

Jefferies Financial

KeyCorp

Berkshire Hathaway

Berkshire Hathaway B

Thomson Reuters

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB increased its stake in HCA Healthcare, Inc. by 7.9% in Q4, owning 213,272 shares valued at approximately $99.57 million. Other hedge funds also adjusted their positions. HCA's stock opened at $422.60, with a market cap of $93.75 billion. The company reported Q1 earnings of $7.15 per share, slightly below estimates, and announced a quarterly dividend of $0.78. Analysts have varied price targets, with UBS raising theirs to $635.00.

HCA Healthcare

Toronto Dominion Bank

ROYAL BANK OF CANADA

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

HIMS

HIMZ

Hims & Hers Health has upsized its private offering of 0% convertible senior notes to $350 million, increased from $300 million. The offering, due June 1, 2032, includes a 13-day option for initial purchasers to buy an additional $52.5 million. Proceeds will fund capped call transactions, support the acquisition of Eucalyptus, and cover general corporate purposes. The offering is expected to close Thursday.

Fidelity

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health Prices Upsized $350 Million Notes Offering

BRK.B

BRK.A

Berkshire Hathaway sold its entire stake in UnitedHealth in Q1 2026, leading to a decline in the insurer's stock. CEO Greg Abel's strategy reflects a shift towards quicker trades, contrasting with Warren Buffett's long-term approach. Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

- Berkshire Hathaway divested its entire UnitedHealth position in Q1 2026, leading to a decline in the insurer's stock.  
- CEO Greg Abel is adopting a strategy of quicker trades and capital redeployment, contrasting with Warren Buffett's long-term investment approach.  
- Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

Berkshire's UnitedHealth exit sends shares lower despite turnaround

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

PUBT

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

HIMY

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Unusual Whales

Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

ATRA

IBBQ

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, of the May 22, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and regulatory prospects, leading to investor damages when the truth emerged.

prnewswire

Atara Biotherap

Invesco Nasdaq Biotechnology ETF

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

LLYX

The company is riding an incredible tailwind.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly stock: Next stop $2,000?

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

Novo Nordisk AS

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

iShares Global Healthcare(IXJ.US)

Barclays Remains a Buy on Bayer (0P6S)

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA